CAPS and serous cystadenoma: Additionally, we found that the presence of CAPS+ cells is not limited to low-grade serous EOC as we detected CAPS+ cells in approximately 85% of serous cystadenomas, borderline tumors, and low-grade carcinomas compare to <40% of HGSOC.